Page last updated: 2024-09-05

regadenoson and HbS Disease

regadenoson has been researched along with HbS Disease in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Belcik, T; Field, JJ; Harmann, LM; Karafin, MS; Linden, J; Lindner, JR; Neuberg, D; Puligandla, M; Wandersee, NJ; Widlansky, M	1
Field, JJ; Linden, J; Nathan, DG	2
Field, JJ	1
Field, J; Keefer, J; Lin, G; Linden, J; Majerus, E; Nathan, DG; Neuberg, D; Okam, M; Onyekwere, O; Ross, A	1
Campigotto, F; Field, JJ; Keefer, J; Lin, G; Linden, J; Majerus, E; Nathan, DG; Neuberg, D; Okam, MM; Onyekwere, O; Ross, A	1

Reviews

2 review(s) available for regadenoson and HbS Disease

Article	Year
The role of adenosine signaling in sickle cell therapeutics. Hematology/oncology clinics of North America, 2014, Volume: 28, Issue:2 Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Anemia, Sickle Cell; Animals; Humans; Purines; Pyrazoles; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Signal Transduction	2014
Targeting iNKT cells for the treatment of sickle cell disease. Clinical immunology (Orlando, Fla.), 2011, Volume: 140, Issue:2 Topics: Adenosine A2 Receptor Antagonists; Anemia, Sickle Cell; Animals; Clinical Trials as Topic; Humans; Lymphocyte Activation; Mice; Natural Killer T-Cells; Purines; Pyrazoles	2011

Trials

3 trial(s) available for regadenoson and HbS Disease

Article	Year
Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease. PloS one, 2019, Volume: 14, Issue:7 Topics: Adenosine A2 Receptor Agonists; Adult; Anemia, Sickle Cell; Contrast Media; Female; Forearm; Humans; Image Enhancement; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Prospective Studies; Purines; Pyrazoles; Regional Blood Flow; Ultrasonography; Young Adult	2019
Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. Transactions of the American Clinical and Climatological Association, 2012, Volume: 123 Topics: Adenosine A2 Receptor Agonists; Anemia, Sickle Cell; Cell Count; Dose-Response Relationship, Drug; Humans; Infusions, Intravenous; Natural Killer T-Cells; Purines; Pyrazoles; Remission Induction; Time Factors; Treatment Outcome	2012
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood, 2013, Apr-25, Volume: 121, Issue:17 Topics: Adenosine A2 Receptor Agonists; Adult; Anemia, Sickle Cell; Case-Control Studies; Female; Flow Cytometry; Humans; Infusions, Intravenous; Interferon-gamma; Male; Natural Killer T-Cells; Phosphorylation; Prognosis; Purines; Pyrazoles; Receptor, Adenosine A2A; Tissue Distribution; Transcription Factor RelA; Vascular Diseases	2013

Other Studies

1 other study(ies) available for regadenoson and HbS Disease

Article	Year
Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease? Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Adhesion; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Drug Design; Endothelial Cells; Glycolipids; Health Services Accessibility; Humans; Inflammation; Natural Killer T-Cells; Purines; Pyrazoles; Selectins	2015

Article

Year

Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease?

Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015

Topics: Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Adhesion; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Drug Design; Endothelial Cells; Glycolipids; Health Services Accessibility; Humans; Inflammation; Natural Killer T-Cells; Purines; Pyrazoles; Selectins

2015